KRAS and acute myeloid leukemia: In contrast to AML patients without KRAS mutations (Non-Krasmut), we observed increased cleaved caspase-1 in Krasmut PBMCs (Fig. 8a, b), indicating increased NLRP3 inflammasome activity in human Krasmut cells compared to non-mutant cells.